Literature DB >> 7636179

Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells.

L Arvanitakis1, N Yaseen, S Sharma.   

Abstract

The normal cell cycle is regulated by several molecules, such as the tumor-suppressor protein pRb, the G1 cyclins, the cyclin-dependent kinases, and their inhibitors. These regulators are targeted by negative growth regulatory signals, such as that provided by TGF-beta. Here, we show that the presence of either wild-type EBV or its transforming latent membrane protein-1 (LMP-1) results in the loss of TGF-beta 1-mediated growth inhibition in human B cells. Chemical cross-linking with 125I-labeled TGF-beta 1 showed an essentially normal TGF-beta receptor profile in EBV-positive and EBV-negative Burkitt's lymphoma cell lines, and these receptors were shown to be functional in transducing signals, as evidenced by the TGF-beta 1-mediated modulation of junB gene expression. However, TGF-beta 1 did not induce dephosphorylation of pRb in EBV (or LMP-1)-positive cells as opposed to EBV-negative cells, suggesting a dichotomy in the TGF-beta 1 signaling pathway leading to separable gene regulatory and growth inhibitory responses. Furthermore, LMP-1 was found to induce the expression of cyclin D2; normal B cells or EBV-negative Burkitt's lymphoma cells do not express D-type cyclins. Taken together, these data point to a potential mechanism underlying EBV-mediated B cell transformation whereby constitutive induction of key cell cycle regulators by LMP-1 can lead to pRb hyperphosphorylation and uncontrolled cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636179

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  The murine gammaherpesvirus 68 v-cyclin gene is an oncogene that promotes cell cycle progression in primary lymphocytes.

Authors:  L F van Dyk; J L Hess; J D Katz; M Jacoby; S H Speck; I V Virgin HW
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  Evolutionary aspects of oncogenic herpesviruses.

Authors:  J Nicholas
Journal:  Mol Pathol       Date:  2000-10

3.  Themed issue: the biology and pathology of the Epstein-Barr virus.

Authors:  P G Murray; L S Young
Journal:  Mol Pathol       Date:  2000-10

4.  Murine gammaherpesvirus 68 cyclin D homologue is required for efficient reactivation from latency.

Authors:  A T Hoge; S B Hendrickson; W H Burns
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 6.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

7.  TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40.

Authors:  Aristides G Eliopoulos; Elyse R Waites; Sarah M S Blake; Clare Davies; Paul Murray; Lawrence S Young
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  Latent infection by γherpesvirus stimulates profibrotic mediator release from multiple cell types.

Authors:  Joshua S Stoolman; Kevin M Vannella; Stephanie M Coomes; Carol A Wilke; Thomas H Sisson; Galen B Toews; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

9.  LMP1 strain variants: biological and molecular properties.

Authors:  Bernardo A Mainou; Nancy Raab-Traub
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

10.  Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.

Authors:  Abhik Saha; Masanao Murakami; Pankaj Kumar; Bharat Bajaj; Karen Sims; Erle S Robertson
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.